Insight Molecular Diagnostics (IMDX) Operating Leases (2019 - 2023)

Insight Molecular Diagnostics (IMDX) has 5 years of Operating Leases data on file, last reported at $2.1 million in Q4 2023.

• Quarterly Operating Leases fell 22.98% year-over-year to $2.1 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $2.1 million (down 22.98% YoY) and the FY2023 annual result came in at $2.1 million, down 22.98% from the prior year.
• Operating Leases eased to $2.1 million in Q4 2023 per IMDX's latest filing, from $2.6 million in the prior quarter.
• The five-year high for Operating Leases was $4.3 million in Q4 2020, with the low at $2.1 million in Q4 2023.
• Average Operating Leases over 5 years is $3.2 million, with a median of $3.2 million recorded in 2022.
• Year-over-year, Operating Leases soared 61.14% in 2020 and decreased 23.33% in 2023.
• Insight Molecular Diagnostics' Operating Leases stood at $2.7 million in 2019, then surged by 61.14% to $4.3 million in 2020, then dropped by 17.79% to $3.5 million in 2021, then slipped by 23.02% to $2.7 million in 2022, then decreased by 22.98% to $2.1 million in 2023.
• Business Quant data shows IMDX's Operating Leases at $2.1 million in Q4 2023, $2.6 million in Q1 2023, and $2.7 million in Q4 2022.